Teacher Retirement System of Texas Decreases Stake in Becton, Dickinson and Company $BDX

Teacher Retirement System of Texas trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 42,097 shares of the medical instruments supplier’s stock after selling 4,206 shares during the quarter. Teacher Retirement System of Texas’ holdings in Becton, Dickinson and Company were worth $7,879,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BDX. Vanguard Group Inc. increased its holdings in Becton, Dickinson and Company by 15.4% during the 2nd quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after purchasing an additional 4,305,947 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 7.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock worth $1,712,715,000 after buying an additional 636,138 shares in the last quarter. First Eagle Investment Management LLC increased its stake in shares of Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after buying an additional 3,268,478 shares during the last quarter. Geode Capital Management LLC raised its holdings in Becton, Dickinson and Company by 3.8% in the second quarter. Geode Capital Management LLC now owns 6,723,702 shares of the medical instruments supplier’s stock valued at $1,153,157,000 after acquiring an additional 244,199 shares in the last quarter. Finally, Norges Bank bought a new position in Becton, Dickinson and Company during the 2nd quarter valued at $653,377,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BDX shares. Piper Sandler dropped their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Bank of America lifted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Finally, Royal Bank Of Canada upped their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Four investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $207.64.

Becton, Dickinson and Company Stock Down 2.0%

Shares of Becton, Dickinson and Company stock opened at $201.84 on Monday. The stock has a market capitalization of $57.51 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 2.23 and a beta of 0.23. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The business’s 50 day simple moving average is $197.40 and its 200-day simple moving average is $190.53.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.91 billion. During the same quarter in the previous year, the firm posted $3.81 EPS. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were issued a $1.05 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Insider Activity

In other news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 2,605 shares of company stock worth $524,643. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.